Are you Dr. Millstine?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 85 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3501 N Scottsdale Rd
Ste 130
Scottsdale, AZ 85251Phone+1 480-425-5000Fax+1 480-425-5033
Summary
- Dr. John Millstine, MD is a board certified nuclear medicine physician in Scottsdale, Arizona. He is currently licensed to practice medicine in Arizona, California, and Washington. He is affiliated with HonorHealth Scottsdale Osborn Medical Center and HonorHealth Scottsdale Shea Medical Center.
Education & Training
- Brigham and Women's Hospital/Harvard Medical SchoolResidency, Nuclear Medicine, 2005 - 2006
- Brigham and Women's Hospital/Harvard Medical SchoolResidency, Radiology-Diagnostic, 2001 - 2005
- UMass Chan Medical SchoolInternship, Internal Medicine, 2000 - 2001
- Vanderbilt University School of MedicineClass of 2000
Certifications & Licensure
- AZ State Medical License 2006 - 2026
- CA State Medical License 2024 - 2026
- WA State Medical License 2008 - 2015
- MA State Medical License 2005 - 2007
- American Board of Nuclear Medicine Nuclear Medicine
- American Board of Radiology Diagnostic Radiology
Publications & Presentations
PubMed
- 19 citationsAppropriate Use Criteria for Bone Scintigraphy in Prostate and Breast Cancer: Summary and Excerpts.Kevin J. Donohoe, Erica J. Cohen, Francesco Giammarile, Erin Grady, Bennett Greenspan
Journal of Nuclear Medicine. 2017-04-01 - 158 citationsPatient management after noninvasive cardiac imaging results from SPARC (Study of myocardial perfusion and coronary anatomy imaging roles in coronary artery disease).Rory Hachamovitch, Benjamin Nutter, Mark A. Hlatky, Leslee J. Shaw, Michael L. Ridner
Journal of the American College of Cardiology. 2012-01-31 - 24 citationsImproved discrimination of benign and malignant lesions on FDG PET/CT, using comparative activity ratios to brain, basal ganglia, or cerebellum.Scott Britz-Cunningham, John Millstine, Victor H. Gerbaudo
Clinical Nuclear Medicine. 2008-10-01